Intended Audience (in order of priority):Nephrologists, Primary Care Physicians, Endocrinologists, Cardiologist, Physician Assistants/Nurse Practitioners, Pharmacists, Managed Care
Bayer TA Rationale for Educational Support:
- Improve understanding of guideline-recommended screening with urine albumin-creatinine ratio (uACR) and estimated glomerular filtration rate (eGFR) for early diagnosis of CKD
- Improve awareness of residual risk of cardio-renal events in patients on standard of care for CKD in T2D (diabetic kidney disease)
- Communicate the complex pathophysiology of CKD progression in T2D patients, with emphasis on mineralocorticoid receptor over activation leading to inflammation of fibrosis as a key driver of disease progression
- Understanding patient profiles and placement in therapy for selective non steroidal mineralocorticoid receptor antagonist
- Emergent therapies for CKD and T2D (Diabetic Kidney Disease) particularly selective non-steroidal mineralocorticoid receptor antagonist
- Clinical differentiation between steroidal and selective non-steroidal mineralocorticoid receptor antagonist
- Selecting the right patients to minimize the risk of hyperkalemia when using non-steroidal mineralocorticoid receptor antagonist
- Multi-disciplinary care of CKD and T2D (Diabetic Kidney Disease) patients
- Overcoming clinical inertia in CKD and T2D (Diabetic Kidney Disease) patients
- Downloadable slides
- Incorporation of social media outreach (You-Tube, FaceBook, Spotify, LinkedIn, Twitter)
- Live Virtual
The proposal must be compliant with standards and guidelines for commercial support (e.g., ACCME).
The proposal should include:
- Needs assessment
- Educational design and rationale for selection (where applicable)
- Learning Objectives
- Proposed Faculty
- Participant recruitment plan (where applicable)
- Outcomes strategy/plan
- Detailed budget (please use the template available on the website)
Copy of most recent accreditation letter and status
Applications/proposals which are submitted and determined to be complete are reviewed monthly. Allow a minimum of 45 days from submission for response.
Acceptance of a Bayer educational grant indicates that you will:
- Reconcile grant funding within 60 days of completion of the educational program
- Permit a Bayer Medical Affairs representative to audit live programs
- Share activity data and outcomes metrics within 30 days of their availability
- Bakris GL, Agarwal R, Anker SD, et al; on behalf of the FIDELIO-DKD study investigators. Design and baseline characteristics of the finerenone in reducing kidney failure and disease progression in diabetic kidney disease trial. Am J Nephrol. 2019;50:333-344.
- Ruilope LM, Agarwal R, Anker SD, et al; on behalf of the FIGARO-DKD study investigators. Design and baseline characteristics of the finerenone in reducing cardiovascular mortality and morbidity in diabetic kidney disease Trial. Am J Nephrol. 2019;50:345-356.
- Bakris GL, Agarwal R, Anker SD, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020; 383:2219-2229 DOI:10.1056/NEJMoa2025845
- Filippatos G, Anker SD, Agarwal R, Pitt B, Ruilope LM, Rossing P, Kolkhof P, Schloemer P, Tornus I, Joseph A, Bakris GL; FIDELIO-DKD Investigators. Finerenone and Cardiovascular Outcomes in Patients with Chronic Kidney Disease and Type 2 Diabetes. Circulation. 2020 Nov 16. doi: 10.1161/CIRCULATIONAHA.120.051898. Epub ahead of print. PMID: 33198491.
- Bakris, GL, Agarwal R, Chan JC, et al. Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial. JAMA. 2015;314(9):884-894.
- Filippatos G, Anker SD, Böhm M, et al. A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease. Eur Heart J. 2016;37(27):2105-2114.
- Pitt B, Anker SD, Böhm M, et al. Rationale and design on mineralocorticoid receptor antagonist tolerability study-heart failure (ARTS-HF): a randomized study of finerenone vs. eplerenone in patients who have worsening chronic heart failure with diabetes and/or chronic kidney disease. Eur J Heart Fail. 2015;17(2):224-232.
- Pitt B, Kober L, Ponikowski P, et al. Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. Eur Heart J. 2013;34(31):2453-2463.
- González-Blázquez R, Somoza B, Gil-Ortega M, et al. Finerenone Attenuates Endothelial Dysfunction and Albuminuria in a Chronic Kidney Disease Model by a Reduction in Oxidative Stress. Front Pharmacol. 2018;9:1131. Published 2018 Oct 9. doi:10.3389/fphar.2018.01131
- Katayama S, Yamada D, Nakayama M, et al. A randomized controlled study of finerenone versus placebo in Japanese patients with type 2 diabetes mellitus and diabetic nephropathy. J Diabetes Complications. 2017;31(4): 758-765.
- Sato N, Ajioka M, Yamada T, et al. A randomized controlled study of finerenone vs. eplerenone in Japanese patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease. Circ J. 2016;80(5):1113-1122.